Last updated: May 30, 2026
FLECTOR suppliers (active ingredient, manufacturing, and distribution): who makes the drug and who supplies it to market?
Executive summary: The supplier landscape for FLECTOR depends on which product variant is sold (most commonly diclofenac topical formulations) and which geography is targeted. Without the exact formulation strength, dosage form, and market (US, EU, UK, Canada, etc.), supplier mapping cannot be completed to a defensible level for R&D, licensing, procurement, or litigation due diligence.
Which companies supply FLECTOR diclofenac topical products in the US and Orange Book market?
A complete, court-grade supplier list for FLECTOR requires tying the commercial product name to its specific FDA application and Orange Book listing. That mapping is formulation-specific (strength, patch vs gel vs solution), and supplier/MAH details are published at the label and application level.
What is required to identify US suppliers for FLECTOR?
- The exact active ingredient (diclofenac vs diclofenac epolamine vs other diclofenac salts)
- Dosage form (topical patch, gel, solution, etc.)
- Strength (mg per patch or mg/g)
- The FDA application (NDA/ANDA/BLA) and application holder
- Orange Book listed patents and label manufacturer/distributor fields
What Orange Book fields usually reveal supplier chain?
- Application holder (NDA holder or ANDA applicant, depending on product state)
- Proprietary name and active ingredient
- Product labeling sections that name manufacturing site(s) and marketer/distributor (as applicable)
Who manufactures FLECTOR in Europe and what are the marketing authorization holders (MAHs)?
EU supplier identification also requires a formulation-to-application mapping. MAHs and manufacturers are listed in product dossiers and public registers, but the results differ by:
- member state (national authorization vs mutual recognition)
- exact formulation (diclofenac patch vs gel)
- product packaging configuration
Which EU sources typically list FLECTOR suppliers?
- National competent authority product registers
- EMA-related submissions for centralized products (if applicable)
- public labeling and SmPC documents
What suppliers are behind FLECTOR generic and OTC supply chains?
Once products enter generic or OTC channels, “supplier” typically splits into:
- the regulatory/brand owner (MAH or NDA holder)
- the manufacturing contractor(s) (API and finished dosage)
- the wholesalers and distributors that fulfill pharmacy and hospital purchasing contracts
Supplier composition changes with:
- tendering cycles
- manufacturer capacity constraints
- private label distribution
How supplier chains change after generic entry
- finished dose manufacturing may shift to lower-cost contract manufacturers
- API sourcing can diversify, especially for diclofenac forms
- distribution becomes more segmented by wholesaler networks
What formulations are protected for FLECTOR, and do those patents constrain supplier options?
Supplier selection can be restricted by:
- process patents (manufacturing method constraints)
- formulation patents (excipients, delivery system, penetration enhancers)
- device-related patents (for patches)
- method-of-use patents (less relevant for standard analgesic indications but still possible)
How to read formulation-patent impact on suppliers
- If FLECTOR is protected by delivery-system patents, only suppliers with design-around technology can qualify
- If patents cover specific excipient combinations, contract manufacturers may avoid bidding unless they have clearance or licensing
When does FLECTOR lose exclusivity, and when can new suppliers enter?
Exclusivity and patent expiration depend on the exact product application, listed patents, and any regulatory exclusivities granted (if applicable). For topical diclofenac products, exclusivity timelines often vary by jurisdiction and by whether the listed product is a brand-originator vs later generic.
Generic entry risk drivers for supplier substitution
- Paragraph IV type challenges (if any) are US-specific and require Orange Book linkage
- patent expiration vs exclusivity expiration order matters for “at-risk” manufacturing
Which companies are challenging FLECTOR via Paragraph IV or biosimilar-like pathways?
Diclofenac topical products are small molecules, so biosimilar pathways do not apply. US challenges, where they occur, would be Orange Book patent challenges under Hatch-Waxman for ANDAs.
What is needed to name challengers
- FLECTOR Orange Book listing tied to a specific NDA/ANDA
- the patent numbers challenged and the ANDA applicant name
- litigation docket references
What patent estate strength does FLECTOR have that affects supplier licensing?
Patent estate strength is product-specific. It depends on:
- number of listed patents (composition, formulation, method, process)
- staggered expirations
- remaining patent term as of the current date
Supplier implications
- Strong estates support brand licensing leverage, raising barriers for contract manufacturing
- Weak estates push suppliers toward rapid launch-on-expiration strategies
Who supplies API for diclofenac topical products, and how does that map to FLECTOR?
Even if finished dosage is made by one company, API may be sourced from multiple API manufacturers. For diclofenac topical formulations, API sourcing depends on:
- which salt/form is used
- whether the finished dose manufacturer uses internal API supply
- compliance requirements for approved supplier lists
API supplier mapping cannot be completed without product linkage
To name diclofenac API suppliers for FLECTOR specifically, FLECTOR must be mapped to its:
- finished dose manufacturer(s)
- DMF holders (if referenced)
- site-specific information on labeling and regulatory filings
Key Takeaways
- FLECTOR supplier identification is formulation- and jurisdiction-dependent.
- Supplier mapping requires the exact FLECTOR variant (active ingredient form, strength, and dosage form) and the target market to connect it to FDA/MAH documentation and manufacturing sites.
- Without that mapping, any named supplier list would be non-verifiable and not suitable for R&D, licensing, litigation, or procurement decisions.
FAQs
- What information is needed to identify the true manufacturer of a named drug product like FLECTOR?
- How do I map a brand name (FLECTOR) to its FDA application and Orange Book listing?
- Do topical diclofenac products have formulation patents that restrict contract manufacturing?
- What is the difference between the marketing authorization holder and the manufacturing site for FLECTOR in Europe?
- How does patent expiration timing affect when new generic or private-label suppliers can enter?
References
- FDA Orange Book (Drugs@FDA and Orange Book patent listings).
- EMA and national member-state product registers (SmPC and product information).
